app_store_button

google_play_button

Device Banner Block-copy 894x1036

Astu lugude lõputusse maailma

Loe ja kuula

Financial Times

From hostile takeovers to C-suite intrigue, Behind the Money takes you inside the business and financial stories of the moment with reporting from Financial Times journalists around the world. 
 Hosted on Acast. See acast.com/privacy for more information.

Behind the Money

In the UK, whistleblowers are encouraged to report wrongdoing, but often at cost to their livelihoods and careers. One solution would be to pay corporate whistleblowers for coming forward. However, many in government have held the idea for years that doing so is not very “British.” But now, longtime opposition to the idea seems to be shifting. Suzi Ring, the FT’s legal correspondent in London, explains how and why. Plus, we speak with Nick Ephgrave, the director of the UK’s Serious Fraud Office, who is taking inspiration from his decades spent with London’s Metropolitan Police Service to try to change the system. 

Clips from ITV

If you missed part one of this series, listen to it here. 

The FT does not use generative AI to voice its podcasts.

- - - - - - - - - - - - - - - - - - - - - - - - - - 

For further reading:

Should corporate whistleblowers get paid?

Whistleblowers could earn millions as HMRC targets tax fraud

UK SFO director pushes to pay whistleblowers and use covert tactics

Corporate whistleblowing in the UK needs a shake-up 

Read a transcript of this episode on FT.com

- - - - - - - - - - - - - - - - - - - - - - - - - - 

Behind the Money host Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more. 

 Hosted on Acast. See acast.com/privacy for more information.

Whistleblowing in the UK, Ep. 2: Is it ‘British’ to pay whistleblowers?

In this special episode of Behind the Money, the FT’s senior business writer Andrew Hill interviews author Stephen Witt about his book The Thinking Machine: Jensen Huang, Nvidia, and the World’s Most Coveted Microchip. Witt and his book won the FT and Schroders Business Book of the Year for 2025. 

The FT does not use generative AI to voice its podcasts.

- - - - - - - - - - - - - - - - - - - - - - - - - - 

For further reading:

In future ‘books could respond’ says winning author Stephen Witt 

FT and Schroders Business Book of the Year 2025 — the shortlist 

FT and Schroders Business Book of the Year 2025 — the longlist 

Read a transcript of this episode on FT.com

- - - - - - - - - - - - - - - - - - - - - - - - - - 

Follow Andrew Hill on X (@andrewtghill) or on Bluesky (@andrewtghill.ft.com) and Stephen Witt (@stephenwitt) on X. Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more. 

 Hosted on Acast. See acast.com/privacy for more information.

Business Book of the Year: Author Stephen Witt on Nvidia’s rise

For years, corporate whistleblowers in the UK have found themselves in an unenviable predicament. They’re encouraged to report wrongdoing, but at the same time they often feel like they’ve risked everything: their careers and livelihoods in exchange for little. In this special two-part series, we explore why critics think this system is failing whistleblowers and what the UK can do to change things.

In part one: We hear from two whistleblowers who share why they blew the whistle and what went wrong after. Plus, the FT’s financial regulation editor Martin Arnold and Mary Inman, the attorney who represented well-known whistleblowers such as Frances Haugen of Meta and Tyler Shultz of Theranos, discuss the systemic issues whistleblowers have faced in the UK. 

Part two airs next Monday, December 15.

The FT does not use generative AI to voice its podcasts.

- - - - - - - - - - - - - - - - - - - - - - - - - - 

For further reading:

Should corporate whistleblowers get paid?

Whistleblowers could earn millions as HMRC targets tax fraud

Corporate whistleblowing in the UK needs a shake-up

Asset management: inside the scandal that rocked GAM 

- - - - - - - - - - - - - - - - - - - - - - - - - - 

Behind the Money host Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more.

Read a transcript of this episode on FT.com

 Hosted on Acast. See acast.com/privacy for more information.

Whistleblowing in the UK, Ep. 1: The cost of speaking up

For years, corporate whistleblowers in the UK have found themselves in an unenviable predicament. They’re encouraged to report wrongdoing, but at the same time they often feel like they’ve risked their livelihoods in exchange for very little in the end. The fallout from whistleblowing can cost them their careers or worse. Starting next Monday, Behind the Money is launching a two-part special series on what, if anything, the UK can do to change this. Listen every Monday on Behind the Money. 
 Hosted on Acast. See acast.com/privacy for more information.

Coming soon: The cost of corporate whistleblowing in the UK

This week we’re sharing an episode from Business History, a podcast from Pushkin Industries. Former Planet Money hosts Jacob Goldstein and Robert Smith explore what the businesses of the past can teach us about commerce today. 

In this episode, Goldstein and Smith look at how Southwest Airlines developed a winning formula that forced its competitors to change how they did business — but then the Southwest model fell apart.

Find Business History on YouTube or wherever you get your podcasts.

 Hosted on Acast. See acast.com/privacy for more information.

Business History: The Secret of Southwest’s Success

When international private equity groups first entered Japan at the turn of the 21st century, newspapers criticised them as vulture funds and politicians steered clear of public contact. Today, it’s a different story. Dozens of buyout groups have set up in the country and the establishment is courting them. The FT’s Tokyo correspondent David Keohane and Tokyo bureau chief Leo Lewis explain why there’s been a shift, and how private equity’s presence may rejuvenate Japanese corporates. Clips from Toho. 

The FT does not use generative AI to voice its podcasts.

- - - - - - - - - - - - - - - - - - - - - - - - - - 

For further reading:

Is Japan private equity’s next frontier?

Buyout firms play the long game beyond Tokyo

Investors sense this time is different for Japan

KKR-owned auto parts supplier Marelli files for US bankruptcy protection 

- - - - - - - - - - - - - - - - - - - - - - - - - - 

Follow David Keohane (@DavidKeo) and Leo Lewis (@Urbandirt) on X. Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more. 

- - - - - - - - - - - - - - - - - - - - - - - - - - 

To sign up for free to the new FT Alphaville newsletter on substack, go to ftav.substack.com

Read a transcript of this episode on FT.com

 Hosted on Acast. See acast.com/privacy for more information.

KKR, Bain and private equity’s push into Japan

Investors are spending billions of dollars on novel ways to extend human life through inventive treatments, therapies, and even manipulating our genes. And increasingly, it seems as though anti-ageing efforts have moved from the super rich to a mass market consumer industry. In this series, we’re covering the past, present and future of the longevity movement. We’ll be looking at where the fixation on longevity is coming from, and trying to understand the practical and ethical issues at the heart of this cutting-edge field of research. 

From Silicon Valley fantasies, to Singaporean health spas, to Colombian genetic clinics and beyond, the FT’s Hannah Kuchler and Michael Peel ask whether breakthroughs in science and technology can really help us live longer, and even stop us aging altogether.

Free to read: 

US ‘wellness’ industry scents opportunity to go mainstream

The quest to make young blood into a drug

This season of Tech Tonic was produced by Josh Gabert-Doyon. The senior producer is Edwin Lane. Flo Phillips is the executive producer. Sound design by Breen Turner and Samantha Giovinco. Fact checking by Simon Greaves, Lucy Baldwin and Tara Cromie. Original music by Metaphor Music. Manuela Saragosa is the FT’s acting co-head of audio.

The FT does not use generative AI to voice its podcasts.

 Hosted on Acast. See acast.com/privacy for more information.

Coming soon from Tech Tonic: Defying death

OpenAI is entering a new era. It's restructured to add a for-profit arm to its business and has signed more than a trillion dollars’ worth of deals to secure chips and build out data centres. But those huge financial commitments also raise massive questions: How will a heavily loss-making company fund $1.4tn worth of deals with some of the biggest publicly listed companies in the world? And what systemic risks could that come with? The FT's US west coast financial editor Tabby Kinder and venture capital correspondent George Hammond answer the questions everyone's asking.

The FT does not use generative AI to voice its podcasts.

Clips from Bg2 Pod, CNBC, Yahoo Finance

- - - - - - - - - - - - - - - - - - - - - - - - - - 

For further reading:

How OpenAI put itself at the centre of a $1tn network of deals

Who owns OpenAI? Blockbuster deals complicate investor payouts

OpenAI shunned advisers on $1.5tn of deals

How high are OpenAI’s compute costs? Possibly a lot higher than we thought

- - - - - - - - - - - - - - - - - - - - - - - - - - 

Attend the FT Global Banking Summit, December 2-4 in London: Enter SAVE20 for a 20% discount, register here.

- - - - - - - - - - - - - - - - - - - - - - - - - - 

Follow Tabby Kinder (@Tabby_Kinder) and George Hammond (@GeorgeNHammond) on X or on Bluesky (@tabbykinder.bsky.social), (@georgehammond.bsky.social). Behind the Money host Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more. 

Read a transcript of this episode on FT.com

 Hosted on Acast. See acast.com/privacy for more information.

What’s the deal with OpenAI's deals?

Pharma juggernauts Pfizer and Novo Nordisk are struggling in the obesity drug race.The two companies are searching for their next moneymaker, and that search recently spun out into a ferocious, multibillion-dollar battle for control of biotech start-up Metsera. The FT’s US deals and activism correspondent Oliver Barnes walks through the tussle that’s involved lawsuits, public barbs and political drama.

Clips from CNBC, Pfizer, Yahoo Finance

- - - - - - - - - - - - - - - - - - - - - - - - - - 

For further reading and listening:

Weight-loss wars: $10bn hostile battle pits Pfizer against Novo Nordisk

Pfizer shows hardball mettle needed to win in 2025 M&A

There is only one winner in the Pfizer Novo Nordisk showdown

Ozempic’s unconventional origins

- - - - - - - - - - - - - - - - - - - - - - - - - - 

Attend the FT Global Banking Summit, 2-4 December in London: Enter SAVE20 for a 20% discount, register here.

- - - - - - - - - - - - - - - - - - - - - - - - - - 

Follow Oliver Barnes on X (@mroliverbarnes), or on Bluesky (@mroliverbarnes.bsky.social) Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more.

Read a transcript of this episode on FT.com

 Hosted on Acast. See acast.com/privacy for more information.

Pfizer and Novo Nordisk’s $10bn battle over weight-loss drugs

Publicly-listed Oklo sits at the intersection of two hot areas for Wall Street: artificial intelligence and energy companies. This year alone, Oklo’s share price has jumped more than 400 per cent. But the business hasn’t generated any revenue. It hasn’t built a nuclear reactor, and it hasn’t secured any binding contracts with customers. The FT’s US energy editor Jamie Smyth explains the enthusiasm for Oklo, its links to the Trump administration and whether it can live up to the hype.

Clips from New York Stock Exchange, The White House, a16z

- - - - - - - - - - - - - - - - - - - - - - - - - - 

For further reading:

Inside Oklo: the $20bn nuclear start-up without any revenue

US and investors gambling on unproven nuclear technology, warn experts

Donald Trump’s assault on US nuclear watchdog raises safety concerns

- - - - - - - - - - - - - - - - - - - - - - - - - - 

Attend the FT Global Banking Summit, 2-4 December in London: Enter SAVE20 for a 20% discount, register here.

- - - - - - - - - - - - - - - - - - - - - - - - - - 

Follow Jamie Smyth on X (@JamieSmythF), or on Bluesky (@jamiesmythft.bsky.social). Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more. 

Read a transcript of this episode on FT.com

 Hosted on Acast. See acast.com/privacy for more information.

The $17bn nuclear start-up without any revenue

The collapse of Silicon Valley Bank last week raised questions about the strength of the United States’ banking system, and whether we’re headed for another financial crisis. The FT’s US financial commentator Robert Armstrong tells us why he’s not freaking out. 

Clips from CBS, NBC, CNN, DW

- - - - - - - - - - - - - - - - - - - - - - - - - - 

For further reading:

SVB was only a little bit insolvent, luckily

SVB’s collapse is not a harbinger of another 2008

The weekend US officials hatched a plan to stave off a banking crisis 

Silicon Valley Bank shows the perils of regulators fighting the last war

For further discussion: 

Join an FT subscriber-only webinar on SVB’s collapse and the fallout, featuring Robert Armstrong and other FT journalists and guests, on Thursday March 16 1600-1700 GMT (1200-1300 ET). Register here. 

- - - - - - - - - - - - - - - - - - - - - - - - - - 

On Twitter, follow Robert Armstrong (@rbrtrmstrng) and Michela Tindera (@mtindera07)

Read a transcript of this episode on FT.com

 Hosted on Acast. See acast.com/privacy for more information.

Why SVB’s collapse is not a 2008 repeat

Loe ja kuula

Muud podcastid, mis võivad sulle meeldida ...